NCT07794670 · Phase 2 · RECRUITING
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
This trial is testing whether obicetrapib, a 10 mg daily tablet, affects people with preclinical Alzheimer's, meaning brain changes without noticeable memory symptoms, compared with a placebo. The source does not say which outcomes are measured. It is a Phase 2 trial, testing whether the drug works and is safe, not yet proven or approved. Details are limited so far.
You may qualify if
- participants with preclinical AD
You're excluded if
- APOE genotype not meeting protocol-defined eligibility criteria
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-09-28